Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2019-11-07 Earnings Release
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Results for the third quarter of 2019
Earnings Release Classification · 98% confidence The document is titled 'Photocure ASA: Results for the third quarter of 2019' and contains detailed financial figures (revenue, EBITDA, net result) for Q3 2019, comparing them to Q3 2018. It discusses business performance, strategic updates (license agreement), and management commentary. This structure strongly indicates a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions a presentation, the core content is the financial results themselves, not just an announcement of the report's release (which would be RPA/RNS). Q3 2019
2019-11-07 English
Photocure ASA: Results for the third quarter of 2019
Earnings Release Classification · 100% confidence The document explicitly states it contains the "Results for the third quarter of 2019" for Photocure ASA. It details key financial metrics for the period (revenue, EBITDA, net result) and discusses business developments specific to that quarter. This content structure aligns perfectly with an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since the text provides detailed financial figures and management commentary on the period's performance, it is more comprehensive than a simple 'Earnings Release' (ER) which usually contains only highlights. It functions as a comprehensive quarterly financial report, fitting the definition of an Interim Report (IR). The document is not merely an announcement of a report (RPA) as it contains the actual results. Q3 2019
2019-11-07 English
Photocure: Cysview® reimbursement further improved from January 2020
Earnings Release Classification · 95% confidence The document is a press release dated November 6, 2019, announcing an improvement in reimbursement rates for the Cysview product by the US Centers for Medicare and Medicaid Services (CMS) effective January 1st, 2020. This type of announcement, detailing specific financial/regulatory outcomes that impact revenue or operations, is characteristic of an Earnings Release (ER) or a general business update. Since it is a formal announcement of a specific financial/operational development rather than a full quarterly/annual report (10-K or IR), and it is not a transcript (CT), management change (MANG), or dividend notice (DIV), the most appropriate classification is Earnings Release (ER), as it communicates key financial performance drivers/updates outside of a formal quarterly filing period. It is not a Report Publication Announcement (RPA) because it contains substantive news, not just a notice that a report is available. FY 2020
2019-11-05 English
Photocure ASA: Invitation to third quarter 2019 results presentation and webcast
Report Publication Announcement Classification · 98% confidence The document is an invitation detailing the time, location, and method (webcast) for the presentation of the company's 'third quarter report' scheduled for November 7, 2019. It explicitly states that the quarterly report and presentation will be published at 07:00 CET and provides registration details. Since the document is short (1016 chars) and its primary function is to announce the upcoming release and presentation of the actual financial report, it fits the definition of a Report Publication Announcement (RPA) rather than the Interim Report (IR) itself. The mention of a 'third quarter report' suggests the underlying document is an IR, but this specific text is the announcement of that release.
2019-10-30 English
Photocure ASA: Invitation to third quarter 2019 results presentation and webcast
Report Publication Announcement Classification · 98% confidence The document is an invitation detailing the time, date, and location for the presentation of the 'third quarter 2019 report'. It explicitly states that the quarterly report and presentation will be published at 07:00 CET and provides webcast details. Since the document itself is an announcement about the upcoming release and presentation of results, rather than the full results (ER) or the comprehensive quarterly report (IR), it fits best as a Report Publication Announcement (RPA). The length (1159 chars) strongly supports this, as it is an invitation/notice, not the full financial document.
2019-10-30 English
Photocure: New data from Hexvix® trials presented at the BLADDR 2019 congress
Regulatory Filings Classification · 95% confidence The document is a press release dated October 28th, 2019, announcing that new data regarding the company's product, Hexvix®, was presented at the BLADDR 2019 congress. It details the findings from two studies and includes quotes from the CEO. This format—a brief announcement highlighting recent corporate or scientific news, often released outside of mandatory SEC filing cycles—is characteristic of a general press release or regulatory announcement. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a formal voting result (DVA), and it serves to disseminate timely corporate information, it best fits the general 'Regulatory Filings' (RNS) category, which acts as a catch-all for significant, non-standard announcements, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is focused on clinical data presentation. Given the content is a scientific/corporate update rather than a financial result summary, RNS is the most appropriate fit as a general regulatory disclosure.
2019-10-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.